PRESS RELEASE – April 17, 2019 (Atlanta) – “The life sciences sector in Georgia is resilient and growing.” This according to a report released today by RTI International (RTI) for Georgia Bio. “ From 2007 to 2017, employment in life sciences grew by 14.9%, compared to 7.7% nationally, and 8.7% growth in private employment across…

At the 2019 Biotechnology Innovation Organization (BIO) DC Fly-In more than 200 biotechnology and life science industry leaders from across the U.S. convened in the District of Columbia to meet with members of Congress and staff to discuss key legislative priorities important to our industry. Georgia Bio had the pleasure of meeting with our senators…

April 17, 2019 | 7:30 – 9:00AM Upstairs Atlanta, 525 Bishop St NW, Atlanta, GA 30318 Join Georgia Bio for a preview of the 2019 Georgia Life Sciences Industry Analysis. This breakfast meeting will provide members, non-members and Georgia community leaders with valuable industry information. The state of the industry report, supported by funding from…

Strokes and cardiovascular disease are taking far too many lives says Dr. Richard Hillstead. These medical issues are ripe for innovation, particularly in minimally invasive opportunities that shorten or eliminate hospital stays while improving patient outcomes. And what about genomics? “I question whether we are as morally and ethically advanced as we are scientifically and…

Dr. Richard Hillstead is both a medtech innovator and a fellow in the American Heart Association on the Council of Clinical Cardiology. He has practiced on the front lines of patient care and life science innovation for decades. Dr. Hillstead, a recipient of a 2019 Industry Growth Award, Georgia Bio’s highest honor, spoke with Write2Market…

With the 2019 Georgia legislative session in full swing and potentially game changing recent comments from U.S. Health and Human Services Secretary Alex Azar, Paul Snyder, VP of Healthcare for Georgia Bio partner Write2Market spoke with Arbor Pharmaceutical CEO Ed Schutter about what the life sciences industry needs from state policy makers in 2019. Paul:…

Two weeks ago, Georgia Bio VP of Business Development and External Affairs Joseph Santoro participated in a Washington fly in to discuss, educate and learn from Congressional legislators, lobbyists and other industry colleagues about the medtech policy climate in the nation’s capital. He shares with us the following top takeaways as formally shared by AdvaMed…

With the development, commercialization and eventual $450 million sale of CardioMEMS, Dr. Jay Yadav demonstrated the magnitude of what is possible in Georgia’s medtech and life sciences ecosystem. Fast forward more than five years and we find him at the helm of MiRus, LLC. MiRus “is focused on the design of innovative solutions for treatment…

By funding research, recruiting scholars, translational and commercialization efforts, GRA plays an integral role in the state’s life science innovation capabilities and industry growth. 2019 will mark the 10th anniversary of the GRA Venture Fund, a public – private venture capital fund that invests in research driven, Georgia-based companies. “We need to introduce [new legislators]…